Tindamax Side Effects
Generic name: tinidazole
Note: This document contains side effect information about tinidazole. Some of the dosage forms listed on this page may not apply to the brand name Tindamax.
Some side effects of Tindamax may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to tinidazole: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking tinidazole (the active ingredient contained in Tindamax) hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
fever, chills, body aches, flu symptoms;
numbness, burning pain, or tingly feeling; or
Less serious side effects of tinidazole may include:
vaginal itching or discharge;
nausea, vomiting, loss of appetite, indigestion;
constipation, diarrhea, stomach cramps;
feeling weak or tired;
headache, dizziness; or
a metallic or bitter taste in your mouth;
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to tinidazole: compounding powder, oral tablet
Gastrointestinal side effects have included metallic/bitter taste (3.7% following a 2 g single dose and 6.3% following multi-day dosing), nausea (3.2% following a 2 g single dose and 4.5% following multi-day dosing), anorexia (1.5% following a 2 g single dose and 2.5% following multi-day dosing), dyspepsia/cramps/epigastric discomfort (1.8% following a 2 g single dose and 1.4% following multi-day dosing), vomiting (1.5% following a 2 g single dose and 0.9% following multi-day dosing), constipation (0.4% following a 2 g single dose and 1.4% following multi-day dosing), tongue discoloration, stomatitis, diarrhea, decreased appetite, and flatulence. Furry tongue and pharyngitis have been reported rarely.
Nervous system side effects have included weakness/fatigue/malaise (2.1% following 2 g single dose and 1.1% following multi-day dosing), dizziness (1.1 % following 2 g single dose and 0.5% following multi-day dosing), convulsions, transient peripheral neuropathy (including numbness and paresthesia), vertigo, ataxia, giddiness, insomnia, and drowsiness.
Oncologic side effects have included mutagenicity in animal studies. Tinidazole (the active ingredient contained in Tindamax) has tested positive for genotoxicity in in vivo studies.
Hepatic side effects have included raised transaminase levels and at least one case report of possible hepatitis.
A possible case of hepatitis was reported in a 4-year-old girl after receiving tinidazole 625 mg orally as a single dose treatment for Giardia. The patient returned to the clinic 6 days following tinidazole therapy with concerns of a 3-day history of progressive ankle swelling. Upon examination she was found to have a 3 g weight gain, marked edema of legs (up to knees), periorbital edema, abdominal distension, ejection flow murmur, liver palpable 6 cm below right coastal margin, no palpable spleen, and clinical evidence of ascites. Laboratory results, upon this admission, were hemoglobin 112 g/L, white cell count 5.2 x 10(9)/L, ESR 14 mm in one hour, sodium 145 mmol/L, potassium 2.6 mmol/L, urea 2.2 mmol/L, total protein 55 g/L, albumin 31 g/L, bilirubin 8 micromoles/L, gamma-glutamyltransferase (GGT) 50 units/L, aspartate aminotransferase (AST) 231 units/L, and creatine phosphokinase 1498 units/L. A chest X-ray, abdominal X-ray, and electrocardiogram showed no abnormalities. Tests for hepatitis A, hepatitis B, leptospirosis, cytomegalovirus, and Epstein-Barr virus were all negative. The patient's parents denied any known contact with infectious hepatitis. The patient was treated with potassium and spironolactone. The patient never became jaundiced. Two weeks later, all serum electrolyte levels and laboratory tests had returned to normal values, edema was absent, liver was palpable 2 cm below right costal margin, and the spleen could just be felt.
Musculoskeletal side effects have included arthralgias, myalgias, and arthritis.
Hypersensitivity side effects have included urticaria, pruritus, rash, flushing, sweating, dryness of mouth, fever, burning sensation, thirst, salivation, and angioedema. Severe acute hypersensitivity reactions (including urticaria, pruritis, angioedema, Stevens-Johnson syndrome, and erythema multiforme) during initial or subsequent tinidazole (the active ingredient contained in Tindamax) exposure have been reported during postmarketing experience.
Ten patients were reported to have hypersensitivity reactions occurring on the same day of oral tinidazole administration. Nine patients were adults receiving 2 g as a single-dose. One patient was a 5-year-old girl receiving 500 mg as a single-dose. Nine reactions were severe and atropine was administered as part of the treatment. The reactions were characterized by urticaria; facial, periorbital, or laryngeal edema; hypotension; bronchospasm; and dyspnea. All patients recovered without further incidence. Note, at the time of these reactions the oral tablets contained tartrazine. It has been hypothesized that the tartrazine was the causative agent for these reactions. However, none of the patients had a history of asthma, atopy, or sensitivity to aspirin or aspirin-like products.
Renal side effects have included darkened urine and urine abnormality.
Cardiovascular side effects have included palpitations.
Hematologic side effects have included transient neutropenia and transient leukopenia. Reversible thrombocytopenia has been reported rarely.
Genitourinary side effects have included increased vaginal discharge, urinary tract infection, dysuria, vulvovaginal discomfort, vaginal odor, menorrhagia, female genital pruritus, and Candida vaginitis.
Respiratory side effects have included upper respiratory tract infection. Bronchospasm and dyspnea have been reported rarely.
Psychiatric sides effects have included rare reports of depression.
Other side effects have included headache (1.3% following a 2 g single dose and 0.7% following multi-day dosing), Candida overgrowth, oral candidiasis, and pelvic pain. Confusion and coma have been reported rarely.
In a study involving 450 patients with fixed drug eruptions, 8 patients were found to have oral tinidazole (the active ingredient contained in Tindamax) as the probable causative agent. The fixed drug eruptions varied as to duration, shape and size, symptoms, number of lesions, and body site(s) affected. The study did not break these factors down for each individual causative agent.
Dermatologic side effects have included reports of fixed drug eruption.
General side effects have included severe toxic reaction (1 case report) following intravenous administration of tinidazole (the active ingredient contained in Tindamax)
A 44-year-old man experienced a severe toxic reaction following administration of tinidazole 1600 mg intravenously over 80 minutes. Within 15 minutes following end of the infusion he fainted and was unconscious for about 10 seconds. The patient experienced some spasms of his left arm, without generalized convulsions, while resuming consciousness. Pharmacologic treatment was not necessary during or following the attack. Low blood pressure, intense nausea, sleepiness, and exhaustion followed the attack and lasted for several hours. The patient's condition gradually improved and he was completely recovered 6 hours after start of attack. Blood samples following infusion showed serum tinidazole level of 35.4 mg/L, normal immunoglobulin E level, and a transient fall in the concentration of complement factor C3.
More Tindamax resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.